Sign up Australia
Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals funded into 2019 through placement

The placement was expanded due to strong demand from investors.
Paul Rennie, CEO and managing director
Paul Rennie, CEO and managing director, is the company's largest shareholder

Paradigm Biopharmaceuticals (ASX:PAR) has completed a share placement to raise $5.75 million by issuing shares priced at $0.30 to institutional, sophisticated and professional investors.

The raising means Paradigm is well funded into CY2019 and importantly, post the completion of the Phase 2 Ross River virus and Phase 2b Osteoarthritis trials due to be completed at the end of CY2018.

In a vote of confidence, Paradigm’s management team participated in the capital raising with Paul Rennie electing to increase his holding by $100,000, subject to shareholder approval.

Paul Rennie, CEO, commented: “The strong support of institutional and sophisticated investors in this capital raising is a solid endorsement of our company and places Paradigm in a very strong position to accelerate our two Phase 2 clinical trials.

“Importantly, it means our company is well-funded post the completion of our key Phase 2 Ross River virus and osteoarthritis trials due to be completed by the end of CY2018.”

Use of funds

The proceeds from the placement will primarily be used to fund:

- The completion of the randomised, double-blind, placebo-controlled Phase 2b clinical trial in 100 subjects with osteoarthritis (OA) and concurrent bone marrow edema lesions (BMELs);
- Ongoing generation of real-world-evidence data in subjects with OA and concurrent BMELs;
- The expansion of the BMEL market into other joint and pain indications;
- The initiation of a pilot Phase 2 clinical trial in Chikungunya;
- Generation of intellectual property; and
- Working capital requirements.


Paradigm is a biotechnology company focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation.

Paradigm is repurposing PPS for a number of applications with a focus on treatment of orthopaedic and viral arthritic indications.

Drug repurposing has the benefits of being lower cost, minimises risk and accelerated development timelines.

Paradigm’s strategy is to establish commercial partnerships with multiple leading pharmaceutical companies.

OA with BMEL clinical trial

Paradigm recently dosed the first participant in the Phase 2b clinical trial investigating the use of PPS in people with knee OA and concurrent BMEL.

One hundred participants will be recruited across five trial sites in Queensland, South Australia, Victoria, and Western Australia with results anticipated in the March quarter of 2019.

READ NOW: Paradigm has successfully dosed first participant in clinical trial for osteoarthritis

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

car-t cells definition
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
scientist with vial
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use